Current treatment strategies for inhibiting mTOR in cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Mammalian target of rapamycin (mTOR) is a key kinase regulating cell growth, proliferation, survival, autophagy, metabolism, and cytoskeletal organization.
• Dysregulated mTOR activity is implicated in various human diseases, notably cancer, driving pharmaceutical interest in mTOR inhibitors.
• While some mTOR inhibitors are approved for specific cancers like advanced renal cell carcinoma, clinical trial success has been limited, necessitating ongoing research.

Purpose of the Study:

• To review the three main classes of mTOR inhibitors currently used in cancer therapy.
• To highlight research efforts in identifying biomarkers for resistance and sensitivity to mTOR inhibition.
• To discuss the potential of these biomarkers in advancing personalized medicine for cancer treatment.

Main Methods:

• Literature review of existing mTOR inhibitors in cancer treatment.
• Analysis of current research on resistance and sensitivity markers for mTOR inhibition.
• Synthesis of information on the evolving role of mTOR inhibitors in oncology.

Main Results:

• Identification and categorization of three classes of mTOR inhibitors for cancer treatment.
• Discussion of the varying clinical success and limitations of current mTOR inhibitors.
• Highlighting the importance of biomarkers for predicting patient response to mTOR-targeted therapies.

Conclusions:

• The landscape of mTOR inhibitors in cancer treatment is dynamic, with ongoing development of new compounds.
• Identifying predictive biomarkers for mTOR inhibition is crucial for developing personalized medicine strategies.
• Further research into resistance and sensitivity markers will refine the clinical application of mTOR inhibitors in oncology.